HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FIFTH CONSECUTIVE YEAR

Harmony Biosciences Holdings (NASDAQ: HRMY) has received the Great Place to Work® recognition for the fifth consecutive year, based on employee feedback that reflects the company's strong workplace culture.

Rhea-AI Summary

Harmony Biosciences Holdings (NASDAQ: HRMY) has received the Great Place to Work® recognition for the fifth consecutive year, based on employee feedback that reflects the company's strong workplace culture. This certification highlights Harmony's commitment to creating an innovative and inclusive environment, as stated by Interim CEO Jeffrey M. Dayno, M.D. Additionally, Harmony was previously recognized as a 'Best Workplace in BioPharma' in 2022 and ranked 4th on Forbes' list of 'America's Best Mid-Sized Companies' in 2023. The company focuses on developing therapies for rare neurological diseases.

Positive

• Achieved 'Great Place to Work®' recognition for five consecutive years.
• Ranked 4th on Forbes' 'America's Best Mid-Sized Companies' list in 2023.
• Previous recognitions include 'Best Workplace in BioPharma' for 2022.

Negative

• None.

Argus Session date unavailable

+1.19% session move Open Argus

Details

News Market Reaction – HRMY

The recorded move for HRMY in the trading session of this news was +1.19%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Recognition reinforces strong company culture and employee experience

PLYMOUTH MEETING, Pa., Feb. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people with rare neurological diseases, today announced the company has earned the Great Place to Work® recognition for the fifth year in a row. The distinction was awarded to Harmony Biosciences based on survey feedback from Harmony employees that verified the quality of the company's culture and their employee experience.

"Earning the Great Place to Work® certification again this year underscores our ongoing commitment to fostering a thriving workplace culture that is innovative, empathetic, inclusive and collaborative," said Jeffrey M. Dayno, M.D., Interim Chief Executive Officer and Chief Medical Officer. "Every day, I see our team of experts from a wide variety of backgrounds and disciplines demonstrate their shared conviction and teamwork in bringing hope to the people and communities we serve. This recognition is a testament to our employees across our entire organization and the important work they do, which I am very proud of."

Harmony's employees completed survey questions regarding employee engagement, workplace culture, diversity and inclusion, company management, innovation, communication, team dynamics and available resources. The results were evaluated against pre-determined criteria for great workplaces through the Great Place to Work® trademarked Trust Index™ and Culture Audit® tool. A summary of these ratings, including how they can be measured against other companies, can be found here.

Harmony Biosciences was recognized by Great Place to Work in 2022 as a "Best Workplace in BioPharma" and in 2019 as a "Best Small and Medium Workplace." Recently, the company ranked 4^th on Forbes list of "America's Best Mid-Sized Companies in 2023."

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

About Great Place to Work®
Great Place to Work® is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, including Best Workplaces lists and workplace reviews, Great Place to Work® provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. In the United States, Great Place to Work® produces the annual Fortune "100 Best Companies to Work For®" list and a series of Great Place to Work® Best Workplaces lists, including lists for Millennials, Women, Diversity, Small and Medium Companies and over a half dozen different industry lists.

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-certified-as-a-great-place-to-work-for-fifth-consecutive-year-301749343.html

SOURCE Harmony Biosciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What recognition did Harmony Biosciences receive in 2023?

Harmony Biosciences was recognized as a 'Great Place to Work®' for the fifth consecutive year.

What is the significance of the Great Place to Work® certification for HRMY?

This certification underscores Harmony's commitment to employee experience and workplace culture.

How has Harmony Biosciences been recognized in previous years?

In 2022, Harmony was recognized as a 'Best Workplace in BioPharma' and ranked 4th on Forbes' list of 'America's Best Mid-Sized Companies' in 2023.

Who is the Interim CEO of Harmony Biosciences?

The Interim CEO of Harmony Biosciences is Jeffrey M. Dayno, M.D.

What does Harmony Biosciences specialize in?

Harmony Biosciences specializes in developing therapies for rare neurological diseases.